Health Canada Has Issued A Notice Of Compliance For Sanofi/Regeneron Dupixent (Dupilumab Injection) For The Treatment Of Patients Aged 1 Year And Older, Weighing At Least 15 Kg, With Eosinophilic Esophagitis
Portfolio Pulse from Benzinga Newsdesk
Health Canada has expanded the approval of Sanofi and Regeneron's Dupixent for treating eosinophilic esophagitis in younger patients, aged 1 year and older, weighing at least 15 kg.
September 12, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron's Dupixent receives expanded approval from Health Canada for younger patients with eosinophilic esophagitis, potentially increasing market reach and sales.
The expanded approval allows Dupixent to be used in a broader patient demographic, which could lead to increased sales and market penetration for Regeneron.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sanofi's Dupixent, co-developed with Regeneron, gains expanded approval in Canada for younger patients, enhancing its market potential.
The approval for a younger patient group can lead to increased sales and market share for Sanofi, as Dupixent can now be prescribed to a wider audience.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80